The Great Biotech Reset

Why Operational Diligence is the New Alpha in Biotech Investing

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

Executive summary

The biotech venture capital ecosystem has completed a dramatic "boom-bust-reset" cycle and is now showing signs of a sustainable, quality-led recovery. However, this recovery is highly bifurcated. Capital is flowing decisively to companies with robust data, de-risked clinical pathways, and operational discipline, while the rest struggle to access funding.[1,5] After a 12-fold boom and an explosive expansion, a severe correction returned the industry to 2012's fundraising levels. The new slow recovery is not a return to the exuberant past; it is the confirmation of a fundamental, permanent market rationalization where execution is the primary currency. The exit market is constrained, initial public offerings (IPOs) are virtually non-existent, and capital is concentrated in the hands of specialist investors making fewer, larger, and longer bets.[1]

In this new environment, capital is too precious to waste. The greatest threat to returns is no longer just scientific risk - **it is operational failure.**

This paper argues that to succeed, Venture Capital (VCs) and Private Equity (PE) investors must address the critical vulnerability in today's market: the **"VC Operational Blindspot."** This blindspot - comprising flawed diligence, unmanaged portfolio fires, and the founder-operator gap - is where promising science becomes a portfolio write-down. HYGEIA Group is the operational partner for biotech investors, providing the deep, CRO-operator expertise required to de-risk investments. We bridge the gap between science and asset value, ensuring capital is deployed efficiently and protected from preventable failures.

---

1. Market Diagnosis: A Fundamental Shift in Biotech Capital

The biotech financing landscape has been fundamentally reshaped. The data reveals four critical shifts that define the new reality for investors:

- **The Boom-Bust-Reset Cycle is Complete:** Biotech VC fundraising returned to roughly $12B in 2024 after peaking at over $152B. Critically, **specialist funds have reclaimed market dominance (72% share in 2024)**, while generalists have retreated.[1] This illustrates a flight to expertise and signals who now controls deployable capital.

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

Public Markets Are Severely Bifurcated: A "great divide" has emerged. While a few winners soar, **approximately 40% of public biotechs were trading below their cash value in April 2025.**[1,2] For preclinical companies, the value destruction has been immense. This signals profound investor skepticism about the operational capabilities of many companies to reach their next value inflection point.[1, 2]

- **Low Enterprise Value is a Trap, not a Safety Net:** The idea that a biotech stock trading at or below cash offers "free upside" is a dangerous misconception. Analysis shows these are often "value traps." In a sector-wide downturn, these companies can fall just as far, if not further, than the broader market. Low enterprise value (EV) is an alert for structural fragility - poor governance, executional failure, competitive displacement - not a signal of temporary mispricing.[3,4]

- **Capital is Concentrated and Demanding:** The market is defined by "fewer rounds but much larger average round sizes." Investors are writing bigger checks but are also demanding **multi-year runways (24–36 months)** to reach de-risking milestones. The bar for new investment has been raised, and only the most operationally sound plans will clear it. [1,3]

- **The Recovery is Selective and led by Mergers and Acquisitions (M&A):** Early signs of IPO market renewal and sustained M&A activity driven by pharma's patent cliff confirm that exits are available, but only for companies that can pass intense, operational due diligence from crossover investors and strategic acquirers.[5] We believe, the recovery is not a rising tide that lifts all boats, but a reward for those who have built seaworthy vessels.[5]

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

Biotech VC fundraising activity



Source: PitchBook • Geography: Global • As of March 31, 2025

Biotech VC capital raised by style ($B)



Source: PitchBook • Geography: Global • As of March 31, 2025

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

3 The Investor Imperative: Closing the Operational Blindspot

The nascent recovery validates this new imperative. A recent report from Massachusetts Biotechnology Council (MassBio) indicates, the comeback is "real this time" precisely because the market is rewarding the operational rigor outlined below.[5] Investors who fail to close these blindspots will be sidelined, even as capital begins to flow more freely.

- ***Prioritize program-level economics:*** Investors and management must rank programs by expected enterprise value (EV) contribution, not by "most advanced" or founder sentiment. The highest-value program should receive the lion's share of scarce capital and management attention.[3]
- ***Runway and cadence expectations:*** Buyers and sophisticated VCs now expect multi-year runway (often 24–36 months) to reach value-inflecting clinical or partnering milestones; shorter runways materially reduce optionality and upgrade probability.[1,3]
- ***Buyer-centric de-risking:*** Design clinical plans and data milestones that directly address likely pharma acquirers' decision criteria: mechanism validation, target population, biomarker evidence, and scalable manufacturing or commercial fit where relevant.[1,3]
- ***Operational transparency and KPIs:*** Real-time operational KPIs (enrollment trends, CRO performance metrics, data-quality indicators, spend-to-milestone burn) materially change investor confidence and are central to rescuing distressed programs or accelerating seller interest.
- ***Financing realism:*** Low EV stocks are not automatic turnaround targets; many reflect structural fragility (poor governance, executional failure, or competitive displacement) rather than temporary mispricing. Low EV should be taken as an alert, not a free upside guarantee. Bottomline - Don't mistake low EV or "cheap at cash" biotech stocks for low-risk investments. They are often value traps or "falling knives", especially in sector panics, unless you have the unique ability to unlock trapped value or time rebounds perfectly. Fundamental diligence and liquidity analysis remain critical to avoid losses. [3,4]

Each of these strategic shifts should be built into both pre-deal diligence and post-deal portfolio governance frameworks. In a market that rewards execution above all else, traditional due diligence is no longer sufficient. Investors must now scrutinize the operational architecture of a company with the same rigor they apply to its science. The

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

"VC Operational Blindspot" is the unmanaged risk that can unravel the most promising investment thesis. This new reality requires a new playbook.

---

4 The Sustainable Recovery Playbook:

Operational due diligence + Portfolio-driven actions.

- ***Pre-deal:*** **Productized Due-Diligence Sprint (4 weeks)**
  - ***Core outputs:*** Program EV rank, critical path milestones, CRO/vendor risk map, 24 to 36-month base and stretch runway models, top 3 single-point-failures and remediation plan.
  - ***Why:*** Identifies "deal-killing operational flaws" before term-sheet commitment and reduces post-investment surprises.
  - ***Pre-IPO/Cross-over Readiness****:* Operational Maturity Audit. Prepare for intense scrutiny from crossover investors by conducting an internal review mirroring their diligence process. Ensure clinical, regulatory, and manufacturing plans are not just sound, but are presented with the granular key performance indicators (KPIs) and risk-mitigation strategies that sophisticated late-stage investors demand.
- ***Post-deal:*** **Portfolio Health & Performance Intelligence**
  - Implement standardized dashboarding (enrollment velocity, site activation lag, protocol deviations, data lock timelines, monthly burn vs milestone) and monthly executive briefings tied to investor KPIs.
  - ***Why:*** Eliminates the portfolio "black box" and provides early warning to redeploy operational support.
- ***Rescue play:*** **Interim Clinical Leadership**
  - Deploy embedded CXO (Project Director / Head of Clinical Ops) to renegotiate underperforming CRO MSAs, re-tie payments to performance metrics, and stabilize execution - targeted savings and enrollment improvements can materially extend runway and restore buyer interest.
- ***M&A and exit readiness:*** **Regulatory-to-Reimbursement Blueprint**

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

- Map IND → approval → payer pathway, identify non-clinical/CMC gaps that block deal structuring, articulate likely price/reimbursement levers for acquirers; prepare contingency-linked deal terms (upfront + milestones) that mirror buyer preferences.

- ***Financing contingency matrix:***
  - For companies trading near or below dissolution value, create prioritized asset sale options, non-dilutive bridge scenarios, and milestone-based syndication pathways to preserve optionality and avoid forced liquidation.[3,4]

HYGEIA's productized service suite maps directly onto these playbook elements, delivering repeatable, investor-facing outputs (sprints, dashboards, interim leadership, integration packages) priced and scoped for rapid deployment. See Appendix B for more details.

---

5 Practical, prioritized checklist for portfolio companies trading below dissolution value [2,3,4]

1. ***Immediate triage (first 30 days)***
   - Reconcile true cash + marketable securities; confirm every line item affecting "cash per share" to avoid valuation misreads.
   - Produce credible 24-month minimum runway model under conservative enrollment and spend assumptions.
2. ***One-program concentration (30–90 days)***
   - Rank programs by NPV and strategic buyer fit; move all discretionary resources to the top program and place others in hibernation or carve-out sale tracks.
3. ***Operational triage (0–90 days)***
   - Implement KPI dashboard for enrollment, site performance, data quality, and CRO SLAs; renegotiate CRO MSAs to include clear performance triggers and clawbacks where appropriate.
4. ***Buyer mapping and commercialization fit (60–120 days)***
   - Prepare one-page buyer profiles aligning lead program milestones to pharma decision triggers (preclinical to IND, phase 2 readouts, biomarker linkage, commercial addressable market).
5. ***Financing contingency and communications (continuous)***

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

- Draft three contingency paths: **(A)** staged milestone financing; **(B)** asset-sale or licensing; **(C)** structured bridge with non-dilutive elements. Communicate transparently to key existing shareholders and likely acquirers.

6. ***Governance and transparency (ongoing)***
    - Replace ad hoc founder reporting with monthly investor briefings driven by the dashboard; require operational KPIs in board packs to reduce asymmetric information and reduce the chance of surprise downgrades.

HYGEIA's case studies show these interventions can restore enrollment, cut fees, and materially improve outcome probabilities - converting distressed assets into viable exit candidates or meaningful value preservation events. See Appendix A.

---

6 How investors should change diligence and portfolio governance [1,3,4]

- ***Move operational due diligence upstream:*** include a productized Operational Diligence Sprint as a gating item before committing to term sheets; require explicit operational remediation plans as part of deal terms.
- ***Demand runway transparency:*** make 24 to 36-month runway scenarios (with execution contingencies) a standard deliverable for any company seeking late-seed to series B financing.
- ***Standardize KPIs across portfolio:*** require a minimal KPI set that allows cross-company benchmarking and early detection of vendor or execution risk.
- ***Build a rapid-response ops team:*** either in-house or via retained specialists (e.g., HYGEIA) to deploy interim clinical leadership when early signals indicate slipping execution.
- ***Incentivize focused capital allocation:*** require board-approved program prioritization and conditional tranche releases tied to operational milestones to avoid diffuse spending that destroys optionality.

These governance changes reduce tail risk, preserve Limited Partner (LP) capital, and position funds to capture outsized returns when the reset produces high-quality, de-risked assets.

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

7 HYGEIA value proposition

- ***What HYGEIA does:*** We convert the sector's new expectations into repeatable outputs for investors - fast operational sprints pre-deal, embedded CXO resources when execution falters, and portfolio dashboards that convert noise into actionable KPIs.
- ***Why this matters now:*** The market rewards fewer, well-executed companies with clear buyer fit; HYGEIA's interventions materially shorten remediation time, reduce cash burn rate through contract and vendor renegotiation, and increase the probability of milestone achievement and orderly exits/ liquidity events.
- ***Productized alignment:*** HYGEIA's fixed-scope offerings (Due-Diligence Sprint, Interim Clinical Leadership, Portfolio Intelligence, Regulatory-to-Reimbursement Blueprints, and M&A Clinical Integration) directly map to investor needs - specialist capital demands, longer runways, and operational transparency.

---

8 Conclusion – Execution is the New Alpha

The Great Biotech Reset is over, and a sustainable recovery is underway. The successful IPOs and strategic M&A highlighted in recent industry analysis are not a sign that we can relax our standards, but proof that the market has permanently shifted from exuberance to a disciplined focus on execution. Capital is flowing to fewer, higher-conviction companies led by specialist investors who demand clear, de-risked, and operationally sound development plans

For investors, the lesson of the recovery is clear: the "alpha" is no longer just in picking the right science, but in ensuring its flawless execution. The companies now leading the comeback - with their advanced assets, proven leaders, and acquirer-ready strategies - are the embodiments of this principle. They are the new blueprint. Those who adapt their diligence and governance to address the operational blindspot will be positioned to capture the outsized returns of this new era. Those who rely on old playbooks will find that this recovery has no place for them

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

9. References:

1. Helal K, Good S. The Evolution of Biotech VC Funds: Navigating selectivity, convergence, and extended timelines in post-peak biotech investing. Seattle, WA: PitchBook Data, Inc.; 2025 May 29.

2. Senior M. Biotech financing: divide and reset. Nature Biotechnology. 2025 Jul;43:1028-1034. Published online 2025 Jun 16.

3. Kolchinsky P. The Way Through This Downturn. RApport [Internet]. Boston, MA: RA Capital Management; 2022 May 27 [cited 2025 Oct 20]. Available from: https://rapport.racap.com/all-stories/the-way-through-the-biotech-downturn

4. Martinez-Forte A. Do stocks trading near cash offer free upside? RApport [Internet]. Boston, MA: RA Capital Management; 2022 Apr 8 [cited 2025 Oct 20]. Available from: https://rapport.racap.com/all-stories/low-ev-stocks-as-free-upside

5. MassBio. "Biotech's Comeback Seems Real This Time: Why Massachusetts is Poised to Lead the Recovery." MassBio.org. 2024. [Link: https://www.massbio.org/news/recent-news/biotechs-comeback-seems-real-this-time-why-massachusetts-is-poised-to-lead-the-recovery/]

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

Appendix A - Case Studies in De-Risking

Our model is proven to protect capital and create value.

- **Case Study 1: Driving a Successful Exit**
  - **Challenge:** A publicly traded biotech with two complex Phase 2 studies.
  - **HYGEIA Solution:** Deployed as a fractional CXO, we restructured vendor management and "implemented a new KPI dashboard". This led to a "critical protocol amendment that accelerated recruitment by 30%".
  - **Result:** The company released positive Phase 2 data, its stock jumped from $7.97 to $26.67, and it was "acquired by large pharma, providing a major liquidity event for VC".

- **Case Study 2: Interim Leadership Turnaround**
  - **Challenge:** A $35M Series B portfolio company's Phase 2 trial was mismanaged, with enrollment "delayed by 6 months" and the CRO cycling through 4 project managers.
  - **HYGEIA Solution:** Deployed as interim Project Director, we "immediately renegotiated the master services agreement with the underperforming CRO, clawing back $250k in fees" and tying all future payments to performance metrics.
  - **Result:** "This intervention salvaged an asset valued at $35M" and preserved the full value of the Series B investment.

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

Appendix B - A Deeper Dive (The Due Diligence Mandate)

For Biotech Venture Capital and Private Equity investors, conducting a robust due diligence is the central pillar of risk management and valuation. At HYGEIA we approach Due Diligence with the following framework in mind:

Due Diligence Must Go Deeper than the "Story" and the Headline Data

- The era of trusting a slick pitch deck and a publication in a high-impact journal is over. Investors must now scrutinize the architecture of the data itself.
- ***Interrogate the Experimental Design:*** Was the preclinical animal model truly predictive? Were the clinical trials designed with proper blinding, randomization, and statistical power? A "positive" result from a poorly designed trial is not an asset; it's a liability. Was an adaptive clinical trial design considered for a seamless Phase I/I or Phase II/III Basket or Platform design for therapeutic areas such as Precision Oncology?
- ***Assess Data Integrity and Transparency:*** Is the raw data available for review to the VC Board member? Are there signs of p-hacking or cherry-picking endpoints? Investors need to look for the "amber" and "red" flags in the company's own data.
- ***Demand Independent Validation:*** Relying solely on the founding team's data is a massive risk. The most sophisticated investors must routinely engage specialist advisors and independent contract research organizations (CROs) to replicate key experiments or hire specialized statistical consulting firms to conduct deep statistical and methodological due diligence.

The "Methodological and Statistical Expertise" Mandate Applies to the Cap Table

- ***Invest in Teams, Not Just Science:*** A brilliant scientist who is dismissive of statistics or robust trial design is a red flag. The ideal team combines domain expertise with strong operational leaders who understand how to generate credible data.
- ***Build it In-House:*** Top-tier biotech funds are now contracting with Expert Networks and Specialty Advisors like HYGEIA Group to critically evaluate potential

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

investments and to provide ongoing oversight for their portfolio companies. Tapping into networks of independent consultants and statisticians during due diligence is non-negotiable. This is no longer a "nice-to-have" but a core cost of underwriting an investment.

Technical Diligence is as Important as Financial and Legal Diligence

- A flawed data package can destroy value more quickly and completely than a bad contract or a weak financial model.
- ***Re-evaluate Valuation Models:*** For Biotech VC and PE investors, the scandal of "red trials" means that the most significant unmanaged risk may no longer be scientific feasibility, but the integrity of the data proving that feasibility. A valuation based on a 90% probability of success for a drug candidate is wildly inflated if the underlying data supporting that candidate comes from a "red" trial. Investors must explicitly discount for "data risk" or "technical risk" in their models. [insert bad trial reference here]
- ***Identify the Point of No Return:*** The biggest capital sinks in biotech are Phase 3 clinical trials. Investing tens of millions into a Phase 3 trial based on flawed Phase 2 data is the ultimate example of "garbage in, garbage out" and a direct route to a total write-off. Rigorous data scrutiny before these inflection points is crucial for capital preservation.

Portfolio Strategy and Governance Require a Focus on Data Rigor

- VCs can no longer just focus on picking winners at the initial investment stage; they have to invest in managing the entire portfolio.
- ***Board-Level Oversight:*** Board members representing the investor must have the capability to question the CMO's trial designs and the CSO's preclinical data packages. They must champion robust data practices and transparent reporting, even when it means delivering bad news sooner.
- ***Capital Allocation as a Lever:*** Investors can use staged financing to mandate specific data quality milestones. For example, the release of a Series B tranche can be contingent on an independent audit of the Phase 2 data or the successful pre-specification of endpoints for Phase 3.

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

The Long-Term View: Building Credibility and Exit Optionality

- Finally, there is the issue of sector-wide and fund-level reputation.
- ***Exit Risk:*** When a large pharma company considers a $1B+ acquisition, their due diligence is exhaustive. If they uncover sloppy data practices or methodological flaws that the original investors missed, the deal can collapse, or the price can be slashed.
- ***The Credibility Currency:*** A fund known for investing in companies with robust, reproducible science builds credibility with co-investors, pharma partners, and the public markets. This credibility lowers the cost of capital and creates more exit opportunities.
- ***Ethical Fiduciary Duty:*** For funds investing in areas that affect patient lives (like most biotech), there is a profound ethical and fiduciary duty. Investing in companies with weak data isn't just a financial risk; it's a bet that could ultimately impact human health, with all the reputational and legal consequences that this entails.
- For Biotech VC and PE investors, the most significant unmanaged risk may no longer be scientific feasibility, but the integrity of the data proving that feasibility.

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com

Let's Start De-Risking Your Next Investment

In the **"Great Biotech Reset,"** you simply cannot afford an operational failure. Before you sign your next term sheet, let us vet the plan. If you have a portfolio asset struggling, let us stabilize it.

Schedule a 30-minute confidential briefing to discuss your current deal flow or portfolio challenges. You can also, request our complimentary **"VC Due Diligence Checklist"** to use on your next deal.

HYGEIA Group
Corporate Headquarters
388 Granton Drive, Suite 200
Richmond Hill, ON, L4B 1H7
Canada

Phone: +1 (905) 841-4752
Email: mjagani@hygeiagroupinc.com
Web: www.hygeiagroupinc.com